SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66
Search This Board:
Last Post: 10/27/2016 4:21:47 AM - Followers: 550 - Board type: Free - Posts Today: 1

MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.

Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  


    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    



yes yes yes yes  



yes yes      



yes yes      



yes yes      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations
Office: 941-637-9883

W. Gerald Newmin, Chairman and Chief Executive Officer

Dr. Steve Chang Ph. D., Director

Grant Miller, Director

Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Current Report Filing (8-k) 09/26/2016 04:12:21 PM
#41677  Sticky Note *** 8-K filing: THESE ARE THE CURRENT MAJOR TPX 09/28/16 03:06:56 PM
#42013   Great. BCLBCL 10/27/16 04:21:47 AM
#42012   14.5M shares? gosh it's amateur hour around here. Dip66 10/26/16 11:15:40 PM
#42011   It's a 10x bagger for me! Party Oneeyedpete 10/26/16 12:22:10 PM
#42010   Immunotherapy Combo Shows Long-lasting Responses in Large Mouse Tumors TPX 10/26/16 11:35:18 AM
#42009   Study Shows How Cancer Cells Evade Immunotherapy, Help TPX 10/26/16 11:24:00 AM
#42008   Knowledge, if anybody really cares about MCET "patents" simon wagstaff 10/26/16 10:51:34 AM
#42007   Its really comical watching these guys pump here. ctvette2003 10/26/16 10:29:05 AM
#42006   14.5M shares here! Let's go! Spread the word! BCLBCL 10/26/16 10:25:56 AM
#42005   Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeu TPX 10/26/16 10:20:12 AM
#42004   $MCET 6 Months Chart http://www.stockscores.c $Pistol Pete$ 10/25/16 10:41:22 PM
#42003   80 bucks? Oh, clean up trade from yesterday? simon wagstaff 10/25/16 05:49:32 PM
#42002   Knowledge, MCET and it's subsidiary already paid the simon wagstaff 10/25/16 03:38:30 PM
#42001   KNOWLEDGE: Another project from Multicell! TPX 10/25/16 02:44:01 PM
#42000   Oxis as of june 30, 2016 had $355,000 simon wagstaff 10/25/16 01:41:14 PM
#41999   Penny Stock Biotech Report 2016-06-15! About OXIS, Multicell,... TPX 10/25/16 01:09:38 PM
#41998   MultiCell gets money for 2 projects OXIS! TPX 10/25/16 01:08:15 PM
#41997   Multicell $540 Million Development and Product License Agreement TPX 10/25/16 01:07:41 PM
#41996   promo crew has lost their mojo here over Dip66 10/25/16 12:33:53 PM
#41995   I believe 5 billion more authorized, they are simon wagstaff 10/25/16 10:10:26 AM
#41994   If anybody really cares they would be wise simon wagstaff 10/25/16 09:53:34 AM
#41993   I know one thing it tells me that presidentsclub 10/25/16 09:16:09 AM
#41992   Each day that passes - is one day BCLBCL 10/25/16 08:29:52 AM
#41991   Smart buy! You will be rewarded soon enough. BCLBCL 10/25/16 08:28:34 AM
#41990   Severely undervalued AND under the radar! Our time BCLBCL 10/25/16 08:27:31 AM
#41989   New immunotherapy study at Sanford centers on colorectal cancer TPX 10/25/16 08:23:23 AM
#41988   Patients find hope in immunotherapy treatment for cancer TPX 10/25/16 08:20:33 AM
#41987   Thank You for sharing. ferenc 10/24/16 11:42:41 PM
#41986   I just emailed them and asked if they ctvette2003 10/24/16 02:38:41 PM
#41985   Do you know why acquired 500m common TPX 10/24/16 01:56:35 PM
#41984   Can anyone state the reasons for buying this stock?? casualriver 10/24/16 01:54:08 PM
#41983   What I think is funny is that the simon wagstaff 10/24/16 01:42:45 PM
#41980   Wake me up when were back over .001+ Dip66 10/24/16 12:25:40 PM
#41979   I bought a few MCET last week Poundthetable 10/24/16 11:37:57 AM
#41978   Where does it say 80% strong buy? I simon wagstaff 10/24/16 10:23:59 AM
#41977   The Future of Immunotherapy Is Not Stopping at TPX 10/24/16 09:43:17 AM
#41976   Cancer immunotherapy is moving fast; Here's what you TPX 10/24/16 09:37:45 AM
#41975   MCET Overall Average: 80% Strong Buy http://www.barc TPX 10/24/16 09:28:08 AM
#41974   Yes . . the bontooth 10/22/16 03:12:24 AM
#41971   Keep talking dirty like that and you might mrroundtree 10/21/16 05:28:59 PM
#41970   911 trades!!! Big news by NOV 1st!!! BCLBCL 10/21/16 12:41:55 PM
#41969   By run, I assume you ate to many ctvette2003 10/20/16 06:19:03 PM
#41968   The run is starting! Don't miss out!! simon wagstaff 10/20/16 02:26:41 PM
#41967   Says the same thing it always has, noting ctvette2003 10/19/16 09:33:31 PM
#41966   Reward will come! Will load again. Who sells TPX 10/19/16 07:07:38 PM
#41965   bid building ... something close ? big green tractor 10/19/16 03:24:29 PM
#41964   The website says a lot: casualriver 10/19/16 03:12:57 PM
#41962   8k said NOTHING. If you really have bought simon wagstaff 10/19/16 02:22:01 PM
#41961   Can't pay the phone bill. simon wagstaff 10/19/16 02:09:00 PM
#41960   Agree! Hit ihub Twitter Facebook friends family / BCLBCL 10/19/16 02:07:16 PM
#41959   Let's bring some attention! Facebook twitter ihub friends BCLBCL 10/19/16 10:14:02 AM